Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Dorothea E. Myers"'
Autor:
Fatih M. Uckun, Lloyd G. Mitchell, Sanjive Qazi, Yang Liu, Nan Zheng, Dorothea E. Myers, Ziyuan Song, Hong Ma, Jianjun Cheng
Publikováno v:
EBioMedicine, Vol 2, Iss 7, Pp 649-659 (2015)
CD22ΔE12 has emerged as a driver lesion in the pathogenesis of pediatric B-lineage acute lymphoblastic leukemia (ALL) and a new molecular target for RNA therapeutics. Here we report a 43-gene CD22ΔE12 signature transcriptome that shows a striking r
Externí odkaz:
https://doaj.org/article/20d686f040cc44bca6c5df3038682c37
Publikováno v:
EBioMedicine, Vol 2, Iss 6, Pp 554-562 (2015)
This study was designed to improve the efficacy of radiation therapy against radiation-resistant leukemia. We report that the potency of low dose radiation therapy against B-precursor acute lymphoblastic leukemia (BPL) can be markedly enhanced by com
Externí odkaz:
https://doaj.org/article/c3e02af4ba5c442b89b739271fb81d35
Publikováno v:
EBioMedicine, Vol 2, Iss 4, Pp 306-316 (2015)
In high-risk remission B-precursor acute lymphoblastic leukemia (BPL) patients, relapse rates have remained high post-hematopoietic stem cell transplantation (HSCT) even after the use of very intensive total body irradiation (TBI)-based conditioning
Externí odkaz:
https://doaj.org/article/1e653eb6c17445698912b1760ef2490f
Autor:
Nan Zheng, Lloyd G. Mitchell, Fatih M. Uckun, Yang Liu, Sanjive Qazi, Ziyuan Song, Hong Ma, Dorothea E. Myers, Jianjun Cheng
Publikováno v:
EBioMedicine
EBioMedicine, Vol 2, Iss 7, Pp 649-659 (2015)
EBioMedicine, Vol 2, Iss 7, Pp 649-659 (2015)
CD22ΔE12 has emerged as a driver lesion in the pathogenesis of pediatric B-lineage acute lymphoblastic leukemia (ALL) and a new molecular target for RNA therapeutics. Here we report a 43-gene CD22ΔE12 signature transcriptome that shows a striking r
Publikováno v:
EBioMedicine, Vol 2, Iss 6, Pp 554-562 (2015)
This study was designed to improve the efficacy of radiation therapy against radiation-resistant leukemia. We report that the potency of low dose radiation therapy against B-precursor acute lymphoblastic leukemia (BPL) can be markedly enhanced by com
Publikováno v:
British Journal of Haematology. 169:401-414
B-precursor acute lymphoblastic leukaemia (BPL) is the most common form of cancer in children and adolescents. Our recent studies have demonstrated that CD22ΔE12 is a characteristic genetic defect of therapy-refractory clones in paediatric BPL and i
Autor:
Zahide Ozer, Hong Ma, Fatih M. Uckun, Rebecca Rose, Dorothea E. Myers, Osmond J. D'Cruz, Sanjive Qazi
Publikováno v:
Journal of Clinical Investigation. 125:1006-1018
Patients with B cell precursor acute lymphoblastic leukemia (BPL) respond well to chemotherapy at initial diagnosis; however, therapeutic options are limited for individuals with BPL who relapse. Almost all BPL cells express CD19, and we recently clo
Publikováno v:
EBioMedicine
EBioMedicine, Vol 2, Iss 4, Pp 306-316 (2015)
EBioMedicine, Vol 2, Iss 4, Pp 306-316 (2015)
In high-risk remission B-precursor acute lymphoblastic leukemia (BPL) patients, relapse rates have remained high post-hematopoietic stem cell transplantation (HSCT) even after the use of very intensive total body irradiation (TBI)-based conditioning
Autor:
Sanjive Qazi, Fatih M. Uckun, Amanda M. Termuhlen, Martha Arellano, Hong Ma, Ingrid Cely, Jianjun Cheng, Anoush Shahidzadeh, Dorothea E. Myers, Seang Yiv, Erin Finestone, Paul S. Gaynon
Publikováno v:
Integrative biology : quantitative biosciences from nano to macro. 6(8)
We report the anti-leukemic potency of a unique biotargeted nanoscale liposomal nanoparticle (LNP) formulation of the spleen tyrosine kinase (SYK) P-site inhibitor C61. C61-loaded LNP were decorated with a murine CD19-specific monoclonal antibody dir
Autor:
Alexandra Levine, Dorothea E. Myers, James T. Casper, Asha Rao, Fatih M. Uckun, Karen O'Neill, Yoav Messinger, Carole Hurvitz, Frederick D. Goldman, Chun-Lin Chen
Publikováno v:
The Journal of Clinical Pharmacology. 39:1248-1255
The authors examined the pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in 17 patients (4 children, 13 adults) with B-lineage lymphoid malignancies, including 12 patients with acute lymphoblastic leukemia (ALL)